Linda Mileshkin - Concepedia

Author

Linda Mileshkin

Also Known As

Ana Mijalkovic Mijalkovic-Lazic, Anne Hamilton, B. Susil, C. Ball, Dr Linda MILESHKIN, Jason Callahan, L Mileshkin, L R Mileshkin, L. Mileshkin, L. R. Mileshkin

554

Publications

31.9K

Citations

H-Index

126

Concepts

All Affiliations

Peter MacCallum Cancer Centre The University of Melbourne Institut Gustave Roussy The University of Sydney Princess Margaret Cancer Centre

About

Linda Mileshkin is an author at Peter MacCallum Cancer Centre specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	34	62	5.6K
2	Health Sciences	10	10	1.1K
3	Public Health	6	6	385
4	Nursing	5	5	91
5	Engineering	2	2	72

Linda Mileshkin

173

Publications

17.6K

Citations

H-Index

Page 1

	Year	Citations
Pan-cancer analysis of whole genomes Lauri A. Aaltonen, Federico Abascal, Adam Abeshouse, Nature	2020	3.1K
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle, The Lancet Oncology Brca1/2 MutationMedicineCancer ManagementGynecologyOlaparib Tablets	2017	1.8K
Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy Alicia León‐Castillo, Stephanie M. de Boer, Melanie Powell, Journal of Clinical Oncology	2020	777
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial Stephanie M. de Boer, Melanie Powell, Linda Mileshkin, The Lancet Oncology	2018	599
Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis Sebastián Morán, Anna Martínez‐Cardús, Sergi Sayols, The Lancet Oncology OncologyTumor HeterogeneityUnknown PrimaryMedicineEpigenetic Change	2016	497
Comprehensive molecular characterization of mitochondrial genomes in human cancers Yuan Yuan, Young Seok Ju, Young-Wook Kim, Nature Genetics	2020	489
Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative Ellen Stelloo, Tjalling Bosse, Remi A. Nout, Modern Pathology Targetable PathwaysTransportec InitiativeHigh-risk Endometrial CancerMedicineCancer Management	2015	476
Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study David M. O’Malley, Giovanni M. Bariani, Philippe A. Cassier, Journal of Clinical Oncology	2022	457
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial Stephanie M. de Boer, Melanie Powell, Linda Mileshkin, The Lancet Oncology	2019	432
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial Andrés Poveda, Anne Floquet, Jonathan A. Ledermann, The Lancet Oncology	2021	391

Page 1